Irinotecan hydrochloride

Irinotecan hydrochloride
Product Description

CAS: 100286-90-6Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Regulatory status: 
USDMF No.23522, USFDA Approved, 
CEP: R0-CEP 2020-025- Rev 00
Stability Studies Zone IVB, WC available

Shenzhen Haorui Industrial Dev. Co. Ltd.

  • CN
  • 2023
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Distributor/Import Export
Manufacturer/Innovator
Pharmaceutical company
Specifications
  • CAS Registry Number
    100286-90-6
  • Details
    USP

Shenzhen Haorui Industrial Dev. Co. Ltd.

  • CN
  • 2023
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Distributor/Import Export
Manufacturer/Innovator
Pharmaceutical company

More Products from Shenzhen Haorui Industrial Dev. Co. Ltd. (2)

  • Dasatinib

    Product Dasatinib

    CAS: 302962-49-8Specification: IHS
    It has a role as a tyrosine kinase inhibitor, an anticoronaviral agent and an antineoplastic agent.
    Regulatory status: USDMF No.34875, local GMP available

  • Docetaxel anhydrous

    Product Docetaxel anhydrous

    CAS: 114977-28-5Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer.
    Regulatory status: USDMF No.22562, USFDA Approved, EU GMP
    CEP: R0-CEP 2021-302-Rev ...